当前位置: X-MOL 学术Nat. Rev. Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Targeting minimal residual disease: a path to cure?
Nature Reviews Cancer ( IF 78.5 ) Pub Date : 2018-01-29 , DOI: 10.1038/nrc.2017.125
Marlise R. Luskin , Mark A. Murakami , Scott R. Manalis , David M. Weinstock

Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disease (MRD), which results in relapse. New functional approaches can characterize clonal heterogeneity and predict therapeutic sensitivity of MRD at a single-cell level. Preliminary evidence suggests that iterative detection, profiling and targeting of MRD would meaningfully improve outcomes and may even lead to cure.



中文翻译:

针对最小残留疾病:治愈的途径?

阻断激酶,转录修饰子,免疫检查点和其他生物脆弱性的疗法正在改变癌症的治疗方法。结果,许多患者达到了惊人的反应,包括放射学或病理学上的完全缓解,但残留的残留病(MRD)却很少,从而导致了复发。新的功能性方法可以表征克隆异质性,并预测单细胞水平上MRD的治疗敏感性。初步证据表明,对MRD进行迭代检测,剖析和靶向可显着改善治疗效果,甚至可能导致治愈。

更新日期:2018-01-29
down
wechat
bug